贝达喹啉在肺结核患者脑脊液中的药代动力学
研究纳入7例利福平耐药肺结核男性患者(2例合并HIV),在24周贝达喹啉治疗期间进行腰椎穿刺及24小时多时点采血,采用优化后的脑脊液收集与保存方法并以液相色谱串联质谱定量。结果显示贝达喹啉及其M2代谢物在所有患者所有时间点脑脊液中均可检出,浓度与血浆中估计的游离部分相似,提示其可自由穿透血脑屏障。
要点
- 贝达喹啉及M2在全部7例患者所有时间点的脑脊液中均可检出。
- 脑脊液浓度与血浆中估计的游离部分相似,提示可自由穿透血脑屏障。
- 作者认为需紧急开展临床研究以确定贝达喹啉对中枢神经系统结核的治疗价值。
核心结论
- 贝达喹啉及其M2代谢物可自由穿透推测血脑屏障完整的肺结核患者脑脊液。
- 作者认为需紧急开展临床研究以确定贝达喹啉能否对中枢神经系统结核治疗产生有意义的作用。
研究设计与样本
- 研究纳入7例已确立24周贝达喹啉治疗的利福平耐药肺结核患者,其中2例合并HIV感染,均为男性。
- 受试者接受腰椎穿刺,并在24小时内多次采血,分别进行脑脊液和血浆药代动力学评估。
- 在定量前,研究者在体外优化了脑脊液收集与保存方法,采用内衬5% BSA溶液的LoBind®管,以捕获预期较低的贝达喹啉和M2浓度(因血浆中蛋白结合率高)。
- 浓度通过液相色谱串联质谱法定量。
主要发现
- 使用内衬5% BSA溶液的LoBind®管,贝达喹啉和M2可在脑脊液中准确测定。
- 贝达喹啉和M2在所有患者的所有时间点均存在,浓度与血浆中估计的游离部分相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With current treatment options most patients with CNS TB develop severe disability or die. Drug-resistant tuberculous meningitis is nearly uniformly fatal. Novel treatment strategies are needed. Bedaquiline, a potent anti-TB drug, has been reported to be absent from CSF in a single report. OBJECTIVES: To explore the pharmacokinetics of bedaquiline and its M2 metabolite in the CSF of patients with pulmonary TB. PATIENTS AND METHODS: Individuals with rifampicin-resistant pulmonary TB established on a 24 week course of treatment with bedaquiline underwent a lumbar puncture along with multiple blood sample collections over 24 h for CSF and plasma pharmacokinetic assessment, respectively. To capture the expected low bedaquiline and M2 concentrations (due to high protein binding in plasma) we optimized CSF collection and storage methods in vitro before concentrations were quantified via liquid chromatography with tandem MS. RESULTS: Seven male participants were enrolled, two with HIV coinfection. Using LoBind® tubes lined with a 5% BSA solution, bedaquiline and M2 could be accurately measured in CSF. Bedaquiline and M2 were present in all patients at all timepoints at concentrations similar to the estimated unbound fractions in plasma. CONCLUSIONS: Bedaquiline and M2 penetrate freely into the CSF of pulmonary TB patients with a presumably intact blood-brain barrier. Clinical studies are urgently needed to determine whether bedaquiline can contribute meaningfully to the treatment of CNS TB.
引用
- Upton CM, Steele CI, Maartens G, et al. Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). J Antimicrob Chemother. 2022. PMID: 35257182. doi:10.1093/jac/dkac067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。